Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2017

Sep 6, 2017

30016_dirs_2017-09-06_0c78bf19-6349-4c92-9870-e2020d54ad7d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2017-09-01

Reporting Person: ESSIG STUART (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-09-01 Deferred Stock Unit $ A 240 Acquired Common Stock (240) Direct
2017-09-01 Non-Qualified Stock Option (right-to-buy) $154.98 A 2532 Acquired 2027-08-31 Common Stock (2532) Direct

Footnotes

F1: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 12, 2017 until the 2018 annual meeting of stockholders.

F2: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2018 annual meeting of stockholders or May 3, 2018, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 3, 2018.

F4: Not applicable.